
News|Articles|July 8, 2026
First Half 2026 Recap: Hepatology
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
First-half 2026 hepatology highlights include FDA approvals, hepatitis B and D advances, MASH progress, and AATD gene editing.
Advertisement
Advertisement
The first half of 2026 marked a transformative period in hepatology, with major regulatory milestones, pivotal late-stage clinical trial results, and continued innovation across viral hepatitis, metabolic liver disease, and rare liver disorders. The
Related to this article

Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.
Advertisement
Advertisement

